Clinical Trial Update: MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MK0991 in combination with standard antifungal therapy for salvage invasive aspergillosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Aspergillosis

Drugs mentioned

• MK0991

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Aspergillosis | Phase 2 | Status: COMPLETED